More Than 1 Million Suicidal Depression Cases Per Year May Be Treated by 2030 via New Indication for Augmentation of Transcranial Magnetic Stimulation: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
Dec 3, 2025, 3:15 PM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The FDA acceptance of ANDA and positive analyst outlook indicate strong market potential.
AI summary
What happened, with direct paths to the underlying reporting
NRXP developing NRX-101 as a breakthrough therapy for suicidal depression. FDA accepted ANDA for preservative-free IV ketamine, KETAFREE™. Analyst D. Boral sets $34 price target for NRXP. New indication for NRX-101 enhances treatment efficacy with TMS. NRXP expects over 1 million TMS treatments annually by 2030.
NRXP developing NRX-101 as a breakthrough therapy for suicidal depression.
FDA accepted ANDA for preservative-free IV ketamine, KETAFREE™.
Analyst D. Boral sets $34 price target for NRXP.
New indication for NRX-101 enhances treatment efficacy with TMS.
NRXP expects over 1 million TMS treatments annually by 2030.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
NRx Pharmaceuticals is scheduled to announce its Q1 earnings on May 18, with analysts projecting a reduced loss per share of 11 cents. Additionally, the company recently received…
NRXP develops NRX-101 for treatment-resistant bipolar depression. FDA received NRXP's ANDA for KETAFREE™, target goal date July 29, 2026. Current ketamine market valued at $750 mi…
FDA gave supportive correspondence for KETAFREE ANDA; GDUFA target Q2 2026. NRXP received expanded Fast Track for NRX-100 and progressed NDA work. Three Florida HOPE clinics now r…
StockNews.AISignal intelligence